{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:43Z","timestamp":1788930523681,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer patients with cardiovascular comorbidities requiring contrast-based cardiac procedures face substantially amplified risk for contrast-induced nephropathy (CIN), driven by anticancer therapy-related systemic inflammation, nephrotoxicity, and endothelial dysfunction. Validated biomarker-based risk stratification tools that capture these distinct pathophysiologic mechanisms are urgently needed in cancer cardiology practice. This study evaluated the combined predictive value of C-reactive protein (CRP), procalcitonin (PCT), and microalbuminuria (MAU) for CIN development following percutaneous coronary intervention (PCI), with direct implications for cardio-oncology risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 486 consecutive patients undergoing elective or urgent PCI between March 2021 and November 2024. Baseline CRP, PCT, and MAU were measured within 24\u2005h pre-procedure. CIN was defined as serum creatinine increase \u22650.5\u2005mg\/dL or \u226525% from baseline within 48\u201372\u2005h post-contrast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CIN developed in 92 patients (18.9%). All three biomarkers independently predicted CIN in multivariable analysis: CRP &amp;gt;10\u2005mg\/L (OR\u2009=\u20093.15,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), PCT &amp;gt;0.05\u2005ng\/mL (OR\u2009=\u20092.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and MAU \u226530\u2005mg\/24\u2005h (OR\u2009=\u20093.42,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). The combined three-biomarker panel demonstrated superior discrimination (AUC\u2009=\u20090.856, 95% CI: 0.818\u20130.894) compared to individual markers (AUC 0.682\u20130.728) and the Mehran score (AUC\u2009=\u20090.714). An additive biomarker score (0\u20133) stratified CIN risk from 5.8% (score 0) to 50.0% (score 3), representing an approximately8.6-fold gradient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined pre-procedural assessment of CRP, PCT, and MAU provided excellent discriminatory ability (AUC=0.856) for CIN prediction, substantially superior to individual biomarkers and traditional clinical risk factors. These complementary markers\u2014capturing systemic inflammation, acute inflammatory stress, and baseline renal endothelial integrity, respectively\u2014offer a clinically practical framework for biomarker-guided risk stratification in a general PCI population. As patients on active systemic anticancer therapy were excluded and patients with a cancer history comprised only a minority of the cohort, the potential extension of this panel to cardio-oncology practice is proposed as a mechanistically motivated hypothesis that requires dedicated validation rather than as a demonstrated application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1899776","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:00Z","timestamp":1788928860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined C-reactive protein, procalcitonin, and microalbuminuria panel for contrast-induced nephropathy risk stratification after percutaneous coronary intervention"],"prefix":"10.3389","volume":"13","author":[{"given":"XueChao","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Cangzhou Central Hospital","place":["Cangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZeXiang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cangzhou Central Hospital","place":["Cangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cangzhou Central Hospital","place":["Cangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the International cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1608991","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart failure association (HFA), the European association of cardiovascular imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B9","first-page":"1937","article-title":"Soluble Fms-like tyrosine kinase-1 and cardiac dysfunction in patients treated with bevacizumab in the adjuvant breast cancer setting","volume":"124","author":"Nohria","year":"2018","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0233433","DOI":"10.1371\/journal.pone.0233433","article-title":"Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol","volume":"15","author":"Werner","year":"2020","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1056\/NEJMra1805256","article-title":"Contrast-associated acute kidney injury","volume":"380","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5K","DOI":"10.1016\/j.amjcard.2006.01.019","article-title":"Epidemiology and prognostic implications of contrast-induced nephropathy","volume":"98","author":"McCullough","year":"2006","journal-title":"Am J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2013.06.016","article-title":"Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry","volume":"7","author":"Tsai","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pharmthera.2017.06.009","article-title":"Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies","volume":"180","author":"Mamoulakis","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cjca.2015.05.013","article-title":"Contrast-induced nephropathy: from pathophysiology to preventive strategies","volume":"32","author":"Azzalini","year":"2016","journal-title":"Can J Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12967-020-02574-8","article-title":"Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches","volume":"18","author":"Kusirisin","year":"2020","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacc.2004.06.068","article-title":"A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation","volume":"44","author":"Mehran","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.jacc.2013.03.026","article-title":"A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention","volume":"61","author":"Gurm","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000329534","article-title":"C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention","volume":"34","author":"Gao","year":"2011","journal-title":"Am J Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/00033197211039921","article-title":"Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: a systematic review and meta-analysis","volume":"73","author":"Lin","year":"2022","journal-title":"Angiology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0003319715573651","article-title":"Procalcitonin as an early predictor of contrast-induced acute kidney injury in patients with acute coronary syndromes who underwent percutaneous coronary intervention","volume":"66","author":"Kurtul","year":"2015","journal-title":"Angiology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12872-019-1137-9","article-title":"Elevated high-sensitivity C-reactive protein combined with procalcitonin predicts high risk of contrast-induced nephropathy after percutaneous coronary intervention","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s11255-021-02818-6","article-title":"Predictive value of preprocedural albuminuria for contrast-induced nephropathy non-recovery in patients undergoing percutaneous coronary intervention","volume":"53","author":"Chen","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e935455","DOI":"10.12659\/MSM.935455","article-title":"Microalbuminuria complicated with low estimated glomerular filtration rate: early risk factors for contrast-induced acute kidney injury after coronary intervention","volume":"28","author":"Hu","year":"2022","journal-title":"Med Sci Monit"},{"key":"B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s40001-024-01782-y","article-title":"Evaluating biomarkers for contrast-induced nephropathy following coronary interventions: an umbrella review on meta-analyses","volume":"29","author":"Mahapatro","year":"2024","journal-title":"Eur J Med Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1710933","article-title":"Outcomes after angiography with sodium bicarbonate and acetylcysteine","volume":"378","author":"Weisbord","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2011.03.001","article-title":"Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN trial)","volume":"108","author":"Patti","year":"2011","journal-title":"Am J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ahj.2010.09.022","article-title":"Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention","volume":"160","author":"Marenzi","year":"2010","journal-title":"Am Heart J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2007.09.019","article-title":"Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography","volume":"51","author":"Kane","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2459\/JCM.0b013e328335227c","article-title":"Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention","volume":"11","author":"Maioli","year":"2010","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.amjcard.2004.03.008","article-title":"Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification","volume":"93","author":"Bartholomew","year":"2004","journal-title":"Am J Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/CIRCINTERVENTIONS.110.955310","article-title":"Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction","volume":"3","author":"Sgura","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"B33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/clc.22060","article-title":"Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the mehran risk score","volume":"36","author":"Wi","year":"2013","journal-title":"Clin Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1136\/hrt.2010.218677","article-title":"Impact of contrast-induced nephropathy with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"97","author":"Wi","year":"2011","journal-title":"Heart"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/s0735-1097(02)01745-x","article-title":"The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions","volume":"39","author":"Best","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1161\/01.cir.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"Rihal","year":"2002","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1899776\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:08Z","timestamp":1788928868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1899776\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2026.1899776"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1899776","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1899776"}}